Coadministered Flu and COVID vaccines were safe and effective, according to a study of a SARS-CoV-2 vaccine candidate and an approved influenza vaccine published in The Lancet Respiratory Medicine.
The results demonstrate that vaccine efficacy and safety appeared to be preserved in those receiving both NVX-CoV2373, Novavax recombinant nanoparticle protein-based COVID-19 vaccine candidate, and Seqirus’ adjuvanted, trivalent seasonal influenza vaccine (aTIV) or a cell-based, quadrivalent seasonal influenza vaccine (QIVc), compared to those vaccinated with NVX-CoV2373 alone. The data confirmed no early safety concerns, with local and systemic reactogenicity largely absent or mild in all groups.
The paper, ‘Safety, immunogenicity, and efficacy of a COVID-19 vaccine (NVX-CoV2373) coadministered with seasonal influenza vaccines: an exploratory substudy of a randomized, observer-blinded, placebo-controlled, phase 3 trial,’ is available here.
While additional research is underway, these findings suggest that coadministered Flu and COVID vaccines may be a viable immunization strategy and may help inform immunization policy on co-administration of COVID-19 and influenza vaccines.
coadministered flu and covid vaccines
Go To Source For Respiratory Therapy Coverage
RT delivers in-depth coverage of the clinical, regulatory, and technology landscape for respiratory therapy—and reaches more than 28,000 key decision-makers and influencers. As one of healthcare’s most important data companies, we facilitate the rapid adoption of medical devices and practice management tools into the industry.